Tirzepatides 5 mg, 10 mg, and 15 mg doses showed A1C reductions of 2.01, 2.24 and 2.30, respectively, surpassing semaglutides 1.86 reduction at the 1 mg dose
For a more comprehensive review on impaired gut signaling during obesity, see ref
The transformative potential is evident in specific contexts: for patients with high cardiovascular risk, substantial obesity, and access to comprehensive care, including nutritional support, GLP-1 agonists offer unprecedented therapeutic benefits
All medications come from licensed 503A compounding pharmacies
Create personalized treatment plan You and your provider will discuss treatment options and develop a personalized care plan for you, which may include medications